<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1008210919
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Multifidera
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Dimethyl Fumarate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2912.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dimethyl Fumarate is a medicine that contains the active substance dimethyl fumarate Dimethyl Fumarate is used to treat relapsing-remitting multiple sclerosis (MS). MS is a long-term condition that affects the central nervous system (CNS), including the brain and the spinal cord. Relapsing-remitting MS is characterized by repeated attacks (relapses) of nervous system symptoms. Symptoms vary from patient to patient but typically include walking difficulties, feeling off balance and visual difficulties. These symptoms may disappear completely when the relapse is over, but some problems may remain. How Dimethyl Fumarate works Dimethyl Fumarate seems to work by stopping the body&rsquo;s defence system from damaging your brain<br />and spinal cord. This may also help to delay future worsening of your MS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Dimethyl Fumarate :  if you are allergic to dimethyl fumarate or any of the other ingredients of this medicine (listed in section 6).<br />Warnings and precautions Dimethyl Fumarate may affect your white blood cell counts, your kidneys and liver. Before you start Dimethyl Fumarate, your doctor will do a blood test to count the number of your white blood cells and will check that your kidneys and liver are working properly. Your doctor will test these periodically during treatment. If your number of white blood cells decreases during treatment, your doctor may consider interrupting your treatment Talk to your doctor before taking Dimethyl Fumarate if you have:<br /> severe kidney disease  severe liver disease  a disease of the stomach or bowel  a serious infection (such as pneumonia)<br />Children and adolescents Dimethyl Fumarate should not be used in children and adolescents below 18 years old. The safety and effectiveness of Dimethyl Fumarate in this age group are not known. Other medicines and Dimethyl Fumarate Tell your doctor or pharmacist if you are taking, have recently taken or might take any medicines, in particular:<br /> medicines that contain fumaric acid esters (fumarates) used to treat psoriasis  medicines that affect the body&rsquo;s immune system including other medicines used to treat MS, such as fingolimod, natalizumab or mitoxantrone or some commonly used cancer treatments<br /> medicines that affect the kidneys including some antibiotics (used to treat infections),<br />&ldquo;water tablets&rdquo; (diuretics), certain types of painkillers (such as ibuprofen and other similar&nbsp;anti-inflammatories and medicines purchased without a doctor&rsquo;s prescription) and medicines that contain lithium<br /> Taking Dimethyl Fumarate with certain types of vaccine (live vaccines) may cause you to get an infection and should therefore be avoided your doctor will advise whether other types of vaccines (non-live vaccines) should be given.<br />Dimethyl Fumarate with food and alcohol<br />Consumption of more than a small quantity (more than 50 ml) of strong alcoholic drinks (more than 30% alcohol by volume, e.g. spirits) should be avoided within an hour of taking Dimethyl Fumarate , as alcohol can interact with this medicine. This could cause inflammation of the stomach (gastritis), especially in people already prone to gastritis.<br />Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Do not use Dimethyl Fumarate if you are pregnant unless you have discussed this with your doctor. Breast-feeding It is not known whether the ingredients in Dimethyl Fumarate pass into breast milk. Dimethyl Fumarate is not to be used during breast-feeding. Your doctor will help you decide whether you should stop breast-feeding, or stop using Dimethyl Fumarate. This involves balancing the benefit of breastfeeding for your child, and the benefit of therapy for you. Driving and using machines The effect of Dimethyl Fumarate on the ability to drive or use machines is not known. Your doctor<br />will tell you whether your illness allows you to drive vehicles and use machines safely.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />Starting dose&nbsp;120 mg twice a day. Take this starting dose for the first 7 days, then take the regular dose. Regular dose 240 mg twice a day. Swallow each capsule whole, with some water. Do not divide, crush, dissolve, suck or chew the capsule as this may increase some side effects. Take Dimethyl Fumarate with food &ndash; it may help to reduce some of the very common side effects (listed in section 4).<br />If you take more Dimethyl Fumarate than you should If you have taken too many capsules, talk to your doctor straight away. You may experience side effects similar to those described below in section 4. If you forget to take Dimethyl Fumarate If you forget or miss a dose, do not take a double dose. You may take the missed dose if you leave at least 4 hours between the doses. Otherwise wait until your next planned dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>burning sensation  hot flush, feeling hot  itchy skin (pruritus)  rash  pink or red blotches on the skin (erythema)<br />Side effects which may show up in your blood or urine tests<br /> low levels of white blood cells (lymphopenia, leucopenia) in the blood. Reduced white blood cells could mean your body is less able to fight an infection. If you have a serious infection (such as pneumonia), talk to your doctor immediately<br /> proteins (albumin) in urine  increase in levels of liver enzymes (ALT, AST) in the blood<br />Uncommon side effects These may affect up to 1 in 100 people:  Allergic reactions (hypersensitivity) Not known (frequency cannot be estimated from the available data)<br /> liver inflammation and increase in levels of liver enzymes (ALT or AST in combination with bilirubin)<br />Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting<br />side effects you can help provide more information on the safety of this medicine.</p><p>Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662 o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000 o</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><br />o Other GCC States:<br />Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious effects Moderately low to very low lymphocyte counts - Lymphocyte counts (a type of white blood cell) may be decreased for a long period of time. Having a low white blood cell count for a long period of time can increase your risk of infection, including a risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). The symptoms of PML may be similar to an MS relapse. Symptoms may include new or worsening weakness on one side of the body; clumsiness; changes in vision, thinking, or memory; or confusion or personality changes lasting for more than several days.<br /> Call your doctor straight away if you experience any of these symptoms&nbsp;Severe Allergic reactions - these are uncommon and may affect up to 1 in 100 people Reddening of the face or body (flushing) is a very common (may affect more than 1 in 10 people) side effect. However, if you become flushed and get any of these signs:<br /> swelling of the face, lips, mouth or tongue  wheezing, difficulty breathing or shortness of breath  dizziness or loss of consciousness<br />then this may represent a severe allergic reaction.  Stop taking Dimethyl Fumarate and call a doctor straight away<br />Very common side effects These may affect more than 1 in 10 people:<br /> reddening of the face or body feeling warm, hot, burning or itchy (flushing)  loose stools (diarrhoea)  feeling sick (nausea)  stomach pain or stomach cramps<br /> Taking your medicine with food can help to reduce the side effects above<br />Substances called ketones, which are naturally produced in the body, very commonly show up in urine tests while taking Dimethyl Fumarate. Talk to your doctor about how to manage these side effects. Your doctor may reduce your dose. Do not reduce your dose unless your doctor tells you to. Common side effects These may affect up to 1 in 10 people:<br /> inflammation of the lining of the intestines (gastroenteritis)  being sick (vomiting)  indigestion (dyspepsia)  inflammation of the lining of the stomach (gastritis)<br /> gastrointestinal disorder</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C. &bull; Store in the original package in order to protect from moisture.</p><p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Dimethyl Fumarate contains The active substance is Dimethyl Fumarate mesylate.&nbsp;</p><p>Dimethyl Fumarate Delayed Release Capsules 240mg :</p><p>Each hard gelatin delayed - release capsule contains 240 mg of dimethyl fumarate. Silicified microcrystalline cellulose, croscormellose sodium, Talc, colloidal silicon dioxide, magnesium stearate, methacrylic acid and Methyl Methacrylate co-polymer, Titanium Dioxide, polysorbate 80, Isopropyl Alcohol, triethyl citrate, methacrylic acid co-polymer type C, Poloxamer 407, calcium silicate, sodium bicarbonate, sodium lauryl sulphate. The capsule shell is composed of Gelatin and Titanium Dioxide. The imprinting ink contains the following inactive ingredients: black iron oxide, potassium hydroxide,<br />propylene glycol, shellac and strong ammonia solution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dimethyl Fumarate Capsules 240mg: White opaque size ‘0EL’ Hard Gelatin Capsules imprinted with ‘H’ on cap and ‘D15’ on body filled
with white to off white Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer Manufacturer<br />Saudi hetero lab Co Ltd. Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia<br />Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                6/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ملتيفيدرا كبسول على المادة الفعالة ثنائي ميثيل الفيورمات</p><p dir="RTL"><strong>يستخدم ملتيفيدرا</strong><strong> لعلاج ا</strong><strong>لتصلب</strong><strong>&nbsp;اللويحي&nbsp;</strong><strong>المتعدد</strong><strong>&nbsp;</strong><strong>MS</strong></p><p dir="RTL">مرض التصلب العصبي المتعدد هو مرض مزمن يؤثر على الجهاز العصبي المركزي (CNS) ، بما في ذلك الدماغ والحبل الشوكي . يتميز الانتكاس الخمودي بنوبات متكررة من أعراض الجهاز العصبي . تختلف الأعراض من مريض لآخر ولكنها عادة ما تشمل صعوبات في المشي والشعور بعدم التوازن والصعوبات البصرية . قد تختفي هذه الأعراض تمامًا عندما ينتهي الانتكاس ، ولكن قد تتبقى بعض المشكلات .</p><p dir="RTL"><strong>كيفية عمل ملتيفيدرا</strong></p><p dir="RTL">يعمل ملتيفيدرا من خلال منع جهاز المناعة الخاص بالجسم من إتلاف الدماغ والحبل الشوكي . قد يساعد هذا أيضًا على تأخير تدهور حالة مرض التصلب العصبي المتعدد مستقبلا .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال ملتيفيدرا كبسول </strong><strong>&nbsp;:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من ثنائي ميثيل الفيورمات أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6) .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">قد يؤثر تناول ملتيفيدرا في عدد خلايا الدم البيضاء والكليتين والكبد . ولذا سيقوم طبيبك بإجراء فحص دم لحساب عدد خلايا الدم البيضاء وسيتحقق من أن الكليتين والكبد يعملان بشكل صحيح قبل البدء في استخدام برنامج العلاج بتناول ملتيفيدرا . وسيختبر طبيبك ذلك دوريًا أثناء العلاج . إذا انخفض عدد خلايا الدم البيضاء أثناء العلاج ، قد يفكر طبيبك في وقف العلاج .</p><p dir="RTL">تحدث إلى طبيبك قبل تناول ملتيفيدرا كبسول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض حاد الكبد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالمعدة أو الأمعاء .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى خطيرة (مثل الالتهاب الرئوي) .</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي استخدام ملتيفيدرا كبسول للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا . حيث أن سلامة وفعالية ملتيفيدرا في هذه الفئة العمرية غير معروفة .</p><p dir="RTL"><strong>أدوية أخرى و ملتيفيدرا كبسول</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول ، أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى . على وجه الخصوص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على استرات حمض الفيوماريك (الفيومارات) المستخدمة لعلاج الصدفية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على جهاز المناعة في الجسم بما في ذلك الأدوية الأخرى المستخدمة لعلاج مرض التصلب العصبي المتعدد ، مثل فينجوليمود أو ناتاليزوماب أو ميتوزانترون أو بعض أدوية السرطان المستخدمة بشكل شائع .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على الكليتين بما في ذلك بعض المضادات الحيوية (المستخدمة لعلاج الالتهابات) ، و &quot;أقراص الماء&quot; (مدرات البول) ، وأنواع معينة من المسكنات (مثل الأيبوبروفين وغيره من مضادات الإلتهاب المماثلة والأدوية التي يتم تناولها بدون وصفة طبية من الطبيب) والأدوية التي تحتوي على مادة الليثيوم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻧﺎول ﺗﮐﻔﯾدرا ﻣﻊ أﻧواع ﻣﻌﯾﻧﺔ ﻣن اﻟﻟﻘﺎح (اﻟﻟﻘﺎﺣﺎت اﻟﺣﯾﺔ) ﻗد ﯾﺳﺑب اﻟﻌدوى ، وﺑﺎﻟﺗﺎﻟﻲ ﯾﺟب ﺗﺟﻧﺑﮫ ﺳﯾﻘوم اﻟطﺑﯾب ﺑﻧﺻحك إذا ﮐﺎن ﯾﻧﺑﻐﻲ تناول أﻧواع أﺧرى ﻣن اﻟﻟﻘﺎﺣﺎت (اﻟﻟﻘﺎﺣﺎت ﻏﯾر اﻟﺣﯾﺔ) .</p><p dir="RTL"><strong>تناول ملتيفيدرا مع الطعام أوالكحول</strong></p><p dir="RTL">لا ينبغي تناول كمية كبيرة (أكثر من 50 مل) من المشروبات الكحولية المركزة (أكثر من 30 ٪ كحول ، مثل الأرواح) خلال ساعة من تناول الملتيفيدرا ، لأنه يمكن أن يتفاعل الكحول مع هذا الدواء . ومن الممكن أن يسبب التهاب بالمعدة ، وخاصة في الأشخاص المعرضين بالفعل لالتهاب المعدة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو في مرحلة الرضاعة الطبيعية ، أو إذا كنت تعتقدين أنك حاملاً أو تخططين لإنجاب طفل ، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء .</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">لا تتناولين ملتيفيدرا إذا كنت حاملاً إلا إذا ناقشت ذلك مع طبيبك .</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">من غير المعروف ما إذا كانت المكونات الموجودة في ملتيفيدرا تمر إلى حليب الثدي . فلا يتم تناول ملتيفيدرا أثناء الرضاعة الطبيعية . سوف يساعدك الطبيب في تحديد ما إذا كان يجب التوقف عن الرضاعة الطبيعية ، أو التوقف عن تناول ملتيفيدرا . هذا يتوقف على تحقيق التوازن بين فائدة الرضاعة الطبيعية لطفلك ، وفائدة العلاج بالنسبة لك .</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">غير معروف تأثير تناول ملتيفيدرا على القدرة على القيادة أو استخدام الآلات . سيخبرك طبيبك ما إذا كان مرضك يسمح لك بقيادة السيارات واستخدام الآلات بأمان .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي تناول الدواء دائما وتماما كما أخبرك طبيبك . استشر طبيبك إذا كنت غير متأكد .</p><p dir="RTL"><strong>جرعة البداية</strong></p><p dir="RTL">120 ملغم مرتين في اليوم .</p><p dir="RTL">يتم تناول جرعة البداية هذه لأول 7 أيام من العلاج ، ثم بعد ذلك يتم تناول الجرعة المعتادة .</p><p dir="RTL"><strong>الجرعة العادية</strong></p><p dir="RTL">240 ملغم مرتين في اليوم .</p><p dir="RTL">يجب ابتلاع الكبسولة كاملة مع كوب من الماء . لا تقسم أو تسحق أو تذوب أو تمتص أو تمضغ الكبسولة لأن هذا قد يزيد من بعض الآثار الجانبية .</p><p dir="RTL">تناول (تکفيدرا) مع الطعام - قد يساعد في تقليل بعض الآثار الجانبية الشائعة جدا (المذكورة في القسم 4) .</p><p dir="RTL"><strong>تناول جرعة زائدة من ملتيفيدرا كبسول </strong></p><p dir="RTL">إذا تناولت جرعة زائدة من ملتيفيدرا كبسول أكثر من الموصى بها ، توجه إلى طبيبك على الفور . قد تواجهك آثارًا جانبية مشابهة لتلك الموضحة أدناه في القسم 4 .</p><p dir="RTL"><strong>إذا نسيت أن تتناول ملتيفيدرا كبسول</strong></p><p dir="RTL">&nbsp;إذا نسيت تناول جرعة ، لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية .</p><p dir="RTL">يمكن تناول الجرعة المنسية حتى 4 ساعات قبل الجرعة التالية . وإلا انتظر حتى الجرعة التالية المخطط لها .</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، من الممكن أن يسبب تناول ملتيفيدرا كبسول في بعض الآثار الجانبية ، على الرغم من عدم حدوثها عند الجميع .</p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL">انخفاض متوسط إلى حاد في عدد الخلايا اللمفاوية (وهي نوع من خلايا الدم البيضاء) وقد يحدث ذك لفترة زمنية طويلة . يمكن أن يؤدي انخفاض عدد خلايا الدم البيضاء لفترة زمنية طويلة إلى زيادة خطر العدوى ، بما في ذلك خطر حدوث عدوى دماغية نادرة تسمى اعتلال&nbsp;بيضاء&nbsp;الدماغ متعدد البؤر التقدمي (PML) . قد تكون أعراض PML مشابهة لانتكاسة MS . قد تشمل الأعراض ضعفًا جديدًا أو متفاقمًا على جانب واحد من الجسم ؛ الحماقات . تغييرات في الرؤية أو التفكير أو الذاكرة ؛ أو تغيرات في الارتباك أو في الشخصية والتي تستمر لأكثر من عدة أيام .</p><p dir="RTL"><strong>اتصل بطبيبك على الفور إذا واجهت أيًا من هذه الأعراض:</strong></p><p dir="RTL">تفاعلات حساسية الشديدة - هذه غير شائعة <em>وقد تؤثر على ما يصل إلى شخص من كل 100 شخص</em></p><p dir="RTL">احمرار في الوجه أو بالجسم - هو أمر شائع جدا (قد يؤثر على أكثر من شخص من كل 10 أشخاص) من الآثار الجانبية . ومع ذلك ، إذا عانيت من هذا الإحمرار أو أي من الأعراض التالية :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين والفم أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز ، صعوبة في التنفس أو ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو فقدان الوعي</p><p dir="RTL">هذه الأعراض تمثل رد فعل تحسسي شديد .</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يجب التوقف عن تناول ملتيفيدرا واستدعاء الطبيب على الفور</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جدا</strong></p><p dir="RTL"><em>قد تؤثر في أكثر من شخص من كل 10 أشخاص:</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه أو الشعور بدفء في الجسم أو السخونة أو الحرقة أو الحكة (احمرار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز رخو (إسهال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة أو تشنجات في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إن تناول الدواء مع الطعام</strong> يمكن أن يساعد في تقليل الآثار الجانبية المذكورة أعلاه</p><p dir="RTL">المواد التي تسمى الكيتونات ، والتي يتم إنتاجها بشكل طبيعي في الجسم ، تظهر بشكل شائع في اختبارات البول أثناء تناول ملتيفيدرا .</p><p dir="RTL"><strong>تحدث إلى طبيبك </strong>حول كيفية التعامل مع هذه الآثار الجانبية . طبيبك قد يقلل الجرعة . لا تخفّض جرعتك إلا إذا أخبرك الطبيب بذلك .</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">قد يؤثر هذا على ما يصل إلى شخص من كل 10 أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة الأمعاء (التهاب المعدة والأمعاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (التقيؤ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المعدة (التهاب المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الجهاز الهضمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحرقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ساخن ، والشعور بالسخونه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة الجلد (الحكة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع وردي أو أحمر على الجلد (حمامي)</p><p dir="RTL"><u>الآثار الجانبية التي قد تظهر في اختبارات الدم أو البول</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم البيضاء (قلة اللمفاويات ، نقص الكريات البيضاء) . يمكن أن يتسبب نقص خلايا الدم البيضاء من قدرة الجسم على مقاومة العدوى . إذا كان لديك عدوى خطيرة (مثل الالتهاب الرئوي) ، تحدث إلى طبيبك على الفور .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور البروتينات (الألبومين) في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستويات إنزيمات الكبد في الدم ( ALT، AST)</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL">قد يؤثر هذا على مايصل إلى شخص من كل 100 شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية (فرط الحساسية)</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التردد من البيانات المتاحة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد وزيادة مستويات إنزيمات الكبد (ALT أو AST مع البيليروبين)</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='font-size:9.0pt;line-height:115%;font-family:"Arial",sans-serif;
  mso-no-proof:yes'><span style='mso-element:field-begin;mso-field-lock:yes'></span></span><span
  dir=LTR></span><span dir=LTR></span><span dir=LTR style='font-size:9.0pt;
  line-height:115%;font-family:"Arial",sans-serif;mso-no-proof:yes'><span
  dir=LTR></span><span dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE
  <span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR style='font-size:9.0pt;line-height:115%;font-family:"Arial",sans-serif;
  mso-no-proof:yes'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ الكبسولات في درجة حرارة أقل من 30 &deg; مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ الكبسولات في عبوتها الأصلية بعيدا عن الرطوبة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ملتيفيدرا كبسول بعد تاريخ انتهاء الصلاحية الموجود على العبوة . تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية . استشرالصيدلي في كيفية التخلص من الأدوية التي لم تعد مطلوبة . حيث أنه من شأن هذه التدابيرالمساعدة على حماية البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ملتيفيدرا 240 ملغم كبسول بطيئة المفعول</strong></p><p dir="RTL">يحتوي كل كبسولة صلبة من الجيلاتين على 240 ملغم من ثنائي ثنائي ميثيل الفيورمات .</p><p dir="RTL">الصواغات الأخرى هي: السليلوز دقيق التبلور المتحجر ، الكروس كارميلوز&nbsp;الصودي ، التلك ، ثاني أكسيد السيليكون الغروية ، ستيرات الماغنيسيوم ، وحامض الميثاكريليك ، بوليمر ميثيل الميثاكريليت ، ثاني أكسيد التيتانيوم ، بوليسوربات 80 ، كحول الآيزوبروبيل ، ثلاثي إيثيل السيترات ، بوليمر نوع &nbsp;C ميثيل حمض الاكريلريك ، بولوكسامير 407 ، سيليكات الكالسيوم ، بيكربونات الصوديوم ، دوديسيل كبريتات صوديوم .</p><p dir="RTL">يتكون غلاف الكبسولة من الجيلاتين وثاني أكسيد التيتانيوم .</p><p dir="RTL">تتم طباعة الكبسولات بحبر أسود يحتوي على أكسيد الحديد الأسود وهيدروكسيد البوتاسيوم والبروبيلين جليكول والشيلاك ومحلول الأمونيا القوي .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ملتيفيدرا كبسولات 240 ملغم:</strong></p><p dir="RTL">كبسولات جيلاتينة صلبة ذات مقاس 0 لونها أبيض معتم مطبوع عليها &quot;H&quot; على الغطاء و &quot;D15&quot; على الجسم مملوءة بحبيبات بحبيبات ذات اللون الأبيض إلى الأبيض القاتم .</p><p dir="RTL"><strong>توافر ملتيفيدرا كبسول:</strong></p><p dir="RTL">يتوافر ملتيفيدرا كبسول في علبة تحتوي على شرائط .</p><p dir="RTL">يتم توفير ملتيفيدرا كبسولات 240 ملغم في علبة تحتوي على 30 كبسولة (3 &times; 10) .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المصنع: هتيرو لاب المحدودة - الهند</p><p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL">شركة هيترو السعودية المحدودة</p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية .&nbsp;&nbsp;</p><p dir="RTL">تليفون: &nbsp;+ 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            6/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  Dimethyl Fumarate 240mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  Dimethyl Fumarate Delayed Release Capsules 240mg 
  Each hard gelatin delayed - release capsule contains 240mg of dimethyl fumarate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Delayed Release Hard Gelatin Capsule 
Dimethyl Fumarate Delayed Release Capsules 240mg 
Light blue opaque size '0el' hard gelatin capsules imprinted with 'H' on cap and 'D15' on body  filled  with white to off white tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dimethyl fumarate Capsules is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (please refer to section 5.1 for important information on the populations for which efficacy has been established).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.&nbsp; <u>Posology</u>&nbsp;</p><p>The starting dose is 120 mg twice a day. After 7 days, the dose is increased to the recommended dose of 240 mg twice a day.</p><p>Temporary dose reduction to 120 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1 month, the recommended dose of 240 mg twice a day should be resumed.</p><p>Dimethyl fumarate Capsules should be taken with food (see section 5.2). For those patients who may experience flushing or gastrointestinal adverse reactions, taking Dimethyl fumarate Capsules with food may improve tolerability (see sections 4.4, 4.5 and 4.8).</p><p>Elderly&nbsp;</p><p>Clinical studies of Dimethyl fumarate Capsules had limited exposure to patients aged 55 years and above, and did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients (see section 5.2). Based on the mode of action of the active substance there are no theoretical reasons for any requirement for dose adjustments in the elderly.</p><p>Renal and hepatic impairment&nbsp;</p><p>Dimethyl fumarate Capsules has not been studied in patients with renal or hepatic impairment. Based on clinical pharmacology studies, no dose adjustments are needed (see section 5.2). Caution should be used when treating patients with severe renal or severe hepatic impairment (see section 4.4).</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Dimethyl fumarate Capsules in children and adolescents aged 10 to 18 years have not been established. No data are available. There is no relevant use of Dimethyl fumarate Capsules in children aged less than 10 years for the indication of relapsing remitting multiple sclerosis. <u>Method of administration</u>&nbsp; For oral use.</p><p>The capsule or its contents should not be crushed, divided, dissolved, sucked or chewed as the enteric-coating of the microtablets prevents irritant effects on the gut.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blood/laboratory tests&nbsp;</p><p>Changes in renal laboratory tests have been seen in clinical trials in subjects treated with Dimethyl fumarate Capsules (see section 4.8). The clinical implications of these changes are unknown. Assessment of renal function (e.g. creatinine, blood urea nitrogen and urinalysis) is recommended prior to treatment initiation, after 3 and 6 months of treatment, every 6 to 12 months thereafter and as clinically indicated.&nbsp;</p><p>Drug-induced liver injury, including liver enzyme increase (&ge; 3 ULN) and elevation of total bilirubin levels (&ge; 2 ULN) can result from treatment with Dimethyl fumarate Capsules. The time to onset can be directly, several weeks or longer. Resolution of the adverse events has been observed after treatment was discontinued. Assessment of serum aminotransferases (e.g. ALT, AST) and total bilirubin levels are recommended prior to treatment initiation and during treatment as clinically indicated.</p><p>Patients treated with Dimethyl fumarate Capsules may develop severe prolonged lymphopenia (see section 4.8). Dimethyl fumarate Capsules has not been studied in patients with pre-existing low lymphocyte counts and caution should be exercised when treating these patients. Prior to initiating treatment with Dimethyl fumarate Capsules, a current complete blood count, including lymphocytes, must be performed. If lymphocyte count is found to be below the normal range, thorough assessment of possible causes should be completed prior to initiation of treatment with Dimethyl fumarate Capsules.</p><p>After starting therapy, complete blood counts, including lymphocytes, must be performed every 3 months.&nbsp;</p><p>Consider interruption of Dimethyl fumarate Capsules in patients with lymphocyte counts &lt;0.5x10<sup>9</sup>/L persisting for more than 6 months. The benefit/risk balance of the therapy should be reconsidered in discussion with the patient in the context of other therapeutic options available. Clinical factors, evaluation of any laboratory and imaging investigations could be included as part of this re-consideration. If treatment is continued despite a persistent lymphocyte count &lt; 0.5x10<sup>9</sup>/L, enhanced vigilance is recommended (see also subsection on PML). Lymphocyte counts should be followed until recovery. Upon recovery and in the absence of alternative treatment options, decisions about whether or not to restart Dimethyl fumarate Capsules after treatment discontinuation should be based on clinical judgement.</p><p>Assess the benefit/risk in patients with lymphocyte counts &ge;0.5 x 10<sup>9</sup>/L and &lt;0.8 x 10<sup>9</sup>/L for more than six months.&nbsp;</p><p>MR imaging&nbsp;</p><p>Before initiating treatment with Dimethyl fumarate Capsules, a baseline MRI should be available (usually within 3 months) as a reference. The need for further MRI scanning should be considered in accordance with national and local recommendations. MRI imaging may be considered as part of increased vigilance in patients considered at increased risk of PML. In case of clinical suspicion of PML, MRI should be performed immediately for diagnostic purposes.</p><p>Progressive Multifocal Leukoencephalopathy (PML)&nbsp;</p><p>PML cases have occurred with Dimethyl fumarate Capsules and other products containing fumarates in the setting of moderate to severe prolonged lymphopenia. PML is an opportunistic infection caused by John-Cunningham virus (JCV), which may be fatal or result in severe disability. PML can only occur in the presence of a JCV infection. If JCV testing is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV antibody test has not been studied in Dimethyl fumarate Capsules treated patients. It should also be noted that a negative anti JCV antibody test (in the presence of normal lymphocyte counts) does not preclude the possibility of subsequent JCV infection.</p><p>At the first sign or symptom suggestive of PML, withhold Dimethyl fumarate Capsules and perform appropriate diagnostic evaluations. The symptoms of PML may be similar to an MS relapse. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.</p><p>Prior treatment with immunosuppressive or immunomodulating therapies&nbsp;</p><p>No studies have been performed evaluating the efficacy and safety of Dimethyl fumarate Capsules when switching patients from other disease modifying therapies to Dimethyl fumarate</p><p>Capsules. The contribution of prior immunosuppressive therapy to the development of PML in Dimethyl fumarate Capsules treated patients is unknown. When switching patients from another disease modifying therapy to Dimethyl fumarate Capsules, the half-life and mode of action of the other therapy should be considered in order to avoid an additive immune effect while at the same time, reducing the risk of reactivation of MS.&nbsp;</p><p>A complete blood count is recommended prior to initiating Dimethyl fumarate Capsules and regularly during treatment (see Blood/laboratory tests above).</p><p>Dimethyl fumarate Capsules can generally be started immediately after discontinuation of interferon or glatiramer acetate.</p><p>Severe renal and hepatic impairment&nbsp;</p><p>Dimethyl fumarate Capsules has not been studied in patients with severe renal or severe hepatic impairment and caution should, therefore, be used in these patients (see section 4.2).</p><p>Severe active gastrointestinal disease&nbsp;</p><p>Dimethyl fumarate Capsules has not been studied in patients with severe active gastrointestinal disease and caution should, therefore, be used in these patients.</p><p>Flushing&nbsp;</p><p>In clinical trials, 34% of Dimethyl fumarate Capsules treated patients experienced flushing. In the majority of patients who experienced flushing, it was mild or moderate in severity.&nbsp;</p><p>In clinical trials, 3 patients out of a total of 2,560 patients treated with Dimethyl fumarate Capsules experienced serious flushing symptoms that were probable hypersensitivity or anaphylactoid reactions. These events were not life-threatening, but led to hospitalisation. Prescribers and patients should be alert to this possibility in the event of severe flushing reactions (see sections 4.2, 4.5 and 4.8). <u>Infections</u>&nbsp;</p><p>In phase III placebo-controlled studies, the incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with Dimethyl fumarate Capsules or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts &lt;0.8x10<sup>9</sup>/L or &lt;0.5x10<sup>9</sup>/L. During treatment with Dimethyl fumarate Capsules in the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% from baseline at one year and then plateaued (see section 4.8). Mean lymphocyte counts remained within normal limits. Patients with lymphocyte counts &lt;0.5x10<sup>9</sup>/L were observed in &lt;1% of patients treated with placebo and 6% of patients treated with Dimethyl fumarate Capsules. In clinical studies (both controlled and uncontrolled), 9% of patients had lymphocyte counts &ge;0.5 x 10<sup>9</sup>/L and &lt;0.8 x 10<sup>9</sup>/L for at least six months. 2% of patients experienced lymphocyte counts &lt;0.5 x 10<sup>9</sup>/L for at least six months. In these patients, the majority of lymphocyte counts remained &lt;0.5 x 10<sup>9</sup>/L with continued therapy.</p><p>If therapy is continued in the presence of moderate to severe prolonged lymphopenia, the risk of an opportunistic infection, including Progressive Multifocal Leukoencephalopathy (PML) cannot be ruled out (please refer to subsection PML above for further details).&nbsp;</p><p>If a patient develops a serious infection, suspending treatment with Dimethyl fumarate Capsules should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Patients receiving Dimethyl fumarate Capsules should be instructed to report symptoms of infections to a physician. Patients with serious infections should not start treatment with Dimethyl fumarate Capsules until the infection(s) is resolved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dimethyl fumarate Capsules has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration. In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.</p><p>Vaccination during treatment with Dimethyl fumarate Capsules has not been studied. It is not known whether treatment with Dimethyl fumarate Capsules might reduce the effectiveness of some vaccines. Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with Dimethyl fumarate Capsules unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating. During treatment with Dimethyl fumarate Capsules, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided.</p><p>In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. Potential drug interaction risks were not identified from in vitro CYP-inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl fumarate and monomethyl fumarate (a primary metabolite of dimethyl fumarate).</p><p>Commonly used medicinal products in patients with multiple sclerosis, intramuscular interferon beta-1a and glatiramer acetate, were clinically tested for potential interactions with dimethyl fumarate and did not alter the pharmacokinetic profile of dimethyl fumarate.&nbsp;</p><p>Administration of 325 mg (or equivalent) non-enteric coated acetylsalicylic acid, 30 minutes prior to Dimethyl fumarate Capsules, over 4 days of dosing, did not alter the pharmacokinetic profile of Dimethyl fumarate Capsules and reduced the occurrence and severity of flushing in a healthy volunteer study. However, long term use of acetylsalicylic acid is not recommended for the management of flushing. Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Dimethyl fumarate Capsules. (see sections 4.2, 4.4 and 4.8).&nbsp;</p><p>Concurrent therapy with nephrotoxic medicinal products (such as aminoglycosides, diuretics, NSAIDs or lithium) may increase the potential of renal adverse reactions (e.g. proteinuria) in patients taking Dimethyl fumarate Capsules (see section 4.8).</p><p>Consumption of moderate amounts of alcohol did not alter exposure to Dimethyl fumarate Capsules and was not associated with an increase in adverse reactions. Consumption of large quantities of undiluted strong alcoholic drinks (more than 30% alcohol by volume) may lead to increased dissolution rates of Dimethyl fumarate Capsules and, therefore, may increase the frequency of gastrointestinal adverse reactions.</p><p>In vitro CYP induction studies did not demonstrate an interaction between Dimethyl fumarate Capsules and oral contraceptives. In an in vivo study, co-administration of Dimethyl fumarate Capsules with a combined oral contraceptive (norgestimate and ethinyl estradiol) did not elicit any relevant change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestogens, however an effect of Dimethyl fumarate Capsules on their exposure is not expected. <u>Paediatric population</u>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy&nbsp;</u></p><p>There are no or limited amount of data from the use of dimethyl fumarate in pregnant women. Animal studies have shown reproductive toxicity (see section 5.3). Dimethyl fumarate Capsules is not recommended during pregnancy and in women of childbearing potential not using appropriate contraception (see section 4.5). Dimethyl fumarate Capsules should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus.</p><p><u>Breast-feeding&nbsp;</u></p><p>It is unknown whether dimethyl fumarate or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue Dimethyl fumarate Capsules therapy. The benefit of breastfeeding for the child and the benefit of therapy for the woman should be taken into account.</p><p><u>Fertility&nbsp;</u></p><p>There are no data on the effects of Dimethyl fumarate Capsules on human fertility. Data from preclinical studies do not suggest that dimethyl fumarate would be associated with an increased risk of reduced fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the ability to drive and use machines have been conducted.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>The most common adverse reactions (incidence &ge;10%) for patients treated with Dimethyl fumarate Capsules were flushing and gastrointestinal events (i.e. diarrhoea, nausea, abdominal pain, abdominal pain upper). Flushing and gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing and gastrointestinal events, these events may continue to occur intermittently throughout treatment with Dimethyl fumarate Capsules. The most commonly reported adverse reactions leading to discontinuation (incidence &gt;1%) in patients treated with Dimethyl fumarate Capsules were flushing (3%) and gastrointestinal events (4%).</p><p>In placebo-controlled and uncontrolled clinical studies, a total of 2,468 patients have received Dimethyl fumarate Capsules and been followed for periods up to 4 years with an overall exposure equivalent to 3,588 person-years. Approximately 1,056 patients have received more than 2 years of treatment with Dimethyl fumarate Capsules. The experience in uncontrolled clinical trials is consistent with the experience in the placebo-controlled clinical trials.</p><p>Tabulated summary of adverse reactions&nbsp;</p><p>Adverse reactions, which were more frequently reported in Dimethyl fumarate Capsules versus placebo-treated patients, are presented in the table below. These data were derived from 2 pivotal Phase 3 placebo-controlled, double-blind clinical trials with a total of 1,529 patients treated with Dimethyl fumarate Capsules and for up to 24 months with an overall exposure of 2,371 personyears (see section 5.1). The frequencies described in the table below are based on 769 patients treated with Dimethyl fumarate Capsules 240 mg twice a day and 771 patients treated with placebo.</p><p>The adverse reactions are presented as MedDRA preferred terms under the MedDRA System Organ Class. The incidence of the adverse reactions below are expressed according to the following categories:</p><p>-&nbsp;&nbsp; Very common (&ge;1/10)</p><p>-&nbsp;&nbsp; Common (&ge;1/100 to &lt;1/10)</p><p>-&nbsp;&nbsp; Uncommon (&ge;1/1, 000 to &lt;1/100)</p><p>-&nbsp;&nbsp; Rare (&ge;1/10, 000 to &lt;1/1,000)</p><p>-&nbsp;&nbsp; Very rare (&lt;1/10,000)</p><p>-&nbsp;&nbsp; Not known (cannot be estimated from the available data)</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Frequency category</strong>&nbsp;</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Gastroenteritis</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Progressive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multifocal</p><p>leukoencephalopathy (PML)<sup> 1</sup></p></td><td colspan="2"><p>Not known&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lymphatic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system</p></td><td style="vertical-align:top"><p>&nbsp;Lymphopenia</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Burning sensation</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hot flush</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" rowspan="8" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain upper&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorder</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug-induced liver injury<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Skin &nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp; subcutaneous &nbsp; tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;Pruritus</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Proteinuria</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td><p><sup>&nbsp;</sup>Feeling hot</p></td><td colspan="2"><p>Common</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Ketones measured in urine</p></td><td colspan="2" style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Albumin urine present&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>White blood cell count decreased&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><sup>1 </sup></strong>Adverse reactions derived only during post marketing experience&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Description of selected adverse reactions&nbsp;</p><p>Flushing&nbsp;</p><p>In the placebo-controlled studies, the incidence of flushing (34% versus 4%) and hot flush (7% versus 2%) was increased in patients treated with Dimethyl fumarate Capsules compared to placebo, respectively. Flushing is usually described as flushing or hot flush, but can include other events (e.g. warmth, redness, itching, and burning sensation). Flushing events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing, these events may continue to occur intermittently throughout treatment with Dimethyl fumarate Capsules. In patients with flushing, the majority had flushing events that were mild or moderate in severity. Overall, 3% of patients treated with Dimethyl fumarate Capsules discontinued due to flushing. The incidence of serious flushing, which may be characterised by generalised erythema, rash and/or pruritus, was seen in less than 1% of patients treated with Dimethyl fumarate Capsules (see sections 4.2, 4.4 and 4.5).&nbsp;</p><p>Gastrointestinal&nbsp;</p><p>The incidence of gastrointestinal events (e.g. diarrhoea [14% versus 10%], nausea [12% versus 9%], upper abdominal pain [10% versus 6%], abdominal pain [9% versus 4%], vomiting [8% versus 5%] and dyspepsia [5% versus 3%]) was increased in patients treated with Dimethyl fumarate Capsules compared to placebo, respectively. Gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience gastrointestinal events, these events may continue to occur intermittently throughout treatment with Dimethyl fumarate Capsules. In the majority of patients who experienced gastrointestinal events, it was mild or moderate in severity. Four per cent (4%) of patients treated with Dimethyl fumarate Capsules discontinued due to gastrointestinal events. The incidence of serious gastrointestinal events, including gastroenteritis and gastritis, was seen in 1% of patients treated with Dimethyl fumarate Capsules (see section 4.2).</p><p>Hepatic function&nbsp;</p><p>In placebo-controlled studies, elevations of hepatic transaminases were observed. The majority of patients with elevations had hepatic transaminases that were &lt;3 times the upper limit of normal (ULN). The increased incidence of elevations of hepatic transaminases in patients treated with Dimethyl fumarate Capsules relative to placebo was primarily seen during the first 6 months of treatment. Elevations of alanine aminotransferase and aspartate aminotransferase &ge;3 times ULN, respectively, were seen in 5% and 2% of patients treated with placebo and 6% and 2% of patients treated with Dimethyl fumarate Capsules.. Discontinuations due to elevated hepatic transaminases were &lt;1% and similar in patients treated with Dimethyl fumarate Capsules or placebo. Elevations in transaminases &ge;3 times ULN with concomitant elevations in total bilirubin &gt;2 times ULN, were not observed in placebo-controlled studies.</p><p>Increase of liver enzymes and cases of drug-induced liver injury (elevations in transaminases &ge;3 times ULN with concomitant elevations in total bilirubin &gt;2 times ULN), have been reported in post marketing experience following Dimethyl fumarate Capsules administration, which resolved upon treatment discontinuation.&nbsp;</p><p>Renal&nbsp;</p><p>In placebo-controlled studies, the incidence of proteinuria was higher in patients treated with Dimethyl fumarate Capsules (9%) compared to placebo (7%). The overall incidence of renal and urinary adverse events was similar for Dimethyl fumarate Capsules and placebo-treated patients. There were no reports of serious renal failure. On urinalysis, the percentage of patients with protein values of 1+ or greater was similar for Dimethyl fumarate Capsules (43%) and placebotreated patients (40%). Typically, laboratory observations of proteinuria were not progressive. Compared to patients treated with placebo, estimated glomerular filtration rate (eGFR) was observed to increase in patients treated with Dimethyl fumarate Capsules, including those</p><p>patients with 2 consecutive occurrences of proteinuria (&ge;1+). &nbsp;Haematological&nbsp;</p><p>In the placebo-controlled studies, most patients (&gt;98%) had normal lymphocyte values prior to initiating treatment. Upon treatment with Dimethyl fumarate Capsules, mean lymphocyte counts decreased over the first year with a subsequent plateau. On average, lymphocyte counts decreased by approximately 30% of baseline value. Mean and median lymphocyte counts remained within normal limits. Lymphocyte counts &lt;0.5x10<sup>9</sup>/l were observed in &lt;1% of patients treated with placebo and 6% of patients treated with Dimethyl fumarate Capsules. A lymphocyte count &lt;0.2x10<sup>9</sup>/l was observed in 1 patient treated with Dimethyl fumarate Capsules and in no patients treated with placebo. The incidence of infections (58% versus 60%) and serious infections (2% versus 2%) was similar in patients treated with placebo or Dimethyl fumarate Capsules. An increased incidence of infections and serious infections was not observed in patients with lymphocyte counts &lt;0.8x10<sup>9</sup>/l or &lt;0.5x10<sup>9</sup>/l. PML has occurred in the setting of moderate to severe prolonged lymphopenia (see section 4.4). A transient increase in mean eosinophil counts was seen during the first 2 months of therapy.&nbsp;</p><p>Laboratory abnormalities&nbsp;</p><p>In the placebo-controlled studies, measurement of urinary ketones (1+ or greater) was higher in patients treated with Dimethyl fumarate Capsules (45%) compared to placebo (10%). No untoward clinical consequences were observed in clinical trials.</p><p>Levels of 1,25-dihydroxyvitamin D decreased in Dimethyl fumarate Capsules treated patients relative to placebo (median percentage decrease from baseline at 2 years of 25% versus 15%, respectively) and levels of parathyroid hormone (PTH) increased in Dimethyl fumarate Capsules treated patients relative to placebo (median percentage increase from baseline at 2 years of 29% versus 15%, respectively). Mean values for both parameters remained within normal range. <u>Reporting of suspected adverse reactions</u>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>o Other GCC States: </em></strong><br />Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdose with Dimethyl fumarate Capsules have been reported. The symptoms described in these cases were consistent with the known adverse event profile of Dimethyl fumarate Capsules. There are no known therapeutic interventions to enhance elimination of Dimethyl fumarate Capsules nor is there a known antidote. In the event of overdose, it is recommended that symptomatic supportive treatment be initiated as clinically indicated.<strong> </strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>.</p><p>Pharmacotherapeutic group: Other nervous system drugs, ATC code: N07XX09</p><p>Mechanism of action&nbsp;</p><p>The mechanism by which dimethyl fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Preclinical studies indicate that dimethyl fumarate pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid-derived 2)like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2dependent antioxidant genes in patients (e.g. NAD(P)H dehydrogenase, quinone 1; [NQO1]).&nbsp;</p><p>Pharmacodynamic effects&nbsp;</p><p>Effects on the immune system&nbsp;</p><p>In preclinical and clinical studies, Dimethyl fumarate Capsules demonstrated anti-inflammatory and immunomodulatory properties. Dimethyl fumarate and monomethyl fumarate, the primary metabolite of dimethyl fumarate, significantly reduced immune cell activation and subsequent release of pro-inflammatory cytokines in response to inflammatory stimuli in preclinical models. In clinical studies with psoriasis patients, dimethyl fumarate affected lymphocyte phenotypes through a down-regulation of pro-inflammatory cytokine profiles (T<sub>H</sub>1, T<sub>H</sub>17), and biased towards anti-inflammatory production (T<sub>H</sub>2). Dimethyl fumarate demonstrated therapeutic activity in multiple models of inflammatory and neuroinflammatory injury. In Phase 3 studies, upon treatment with Dimethyl fumarate Capsules mean lymphocyte counts decreased on average by approximately 30% of their baseline value over the first year with a subsequent plateau.&nbsp;</p><p>&nbsp;</p><p>Effect on cardiovascular system&nbsp;</p><p>Single doses of 240 mg or 360 mg Dimethyl fumarate Capsules did not have any effect on the QTc interval when compared to placebo in a QTc study.</p><p>Clinical efficacy and safety&nbsp;</p><p>Two, 2-year, randomised, double-blind, placebo controlled studies [Study 1 (DEFINE) with 1234 subjects and Study 2 (CONFIRM) with 1417 subjects] of subjects with relapsing-remitting multiple sclerosis (RRMS) were performed. Subjects with progressive forms of MS were not included in these studies. Efficacy (see table below) and safety were demonstrated in subjects with Expanded Disability Status Scale (EDSS) scores ranging from 0 to 5 inclusive, who had experienced at least 1 relapse during the year prior to randomisation, or, within 6 weeks of randomisation had a brain Magnetic Resonance Imaging (MRI) demonstrating at least one gadolinium-enhancing (Gd+) lesion. Study 2 contained a rater-blinded (i.e. study physician/ investigator assessing the response to study treatment was blinded) reference comparator of glatiramer acetate.&nbsp;</p><p>In Study 1, patients had the following median baseline characteristics: age 39 years, disease duration 7.0 years, EDSS score 2.0. In addition, 16% of patients had an EDSS score &gt;3.5, 28% had &ge;2 relapses in the prior year and 42% had previously received other approved MS treatments. In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).&nbsp;</p><p>In Study 2, patients had the following median baseline characteristics: age 37 years, disease duration 6.0 years, EDSS score 2.5. In addition, 17% of patients had an EDSS score &gt;3.5, 32% had &ge;2 relapses in the prior year and 30% had previously received other approved MS treatments. In the MRI cohort 45% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 2.4).&nbsp;</p><p>Compared to placebo, subjects treated with Dimethyl fumarate Capsules had a clinically meaningful and statistically significant reduction on: the primary endpoint in Study 1, proportion of subjects relapsed at 2 years; and the primary endpoint in Study 2, annualised relapse rate at 2 years.&nbsp;</p><p>The annualised relapse rate for glatiramer acetate and placebo was 0.286 and 0.401 respectively in Study 2, corresponding to a reduction of 29% (p=0.013), which is consistent with approved prescribing information.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>DEFINE</strong>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>CONFIRM</strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dimethyl fumarate Capsules</strong>&nbsp; <strong>240 mg </strong>&nbsp;<strong>twice a day</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dimethyl fumarate Capsules</strong>&nbsp; <strong>240 mg</strong>&nbsp; <strong>twice a day</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Glatiramer acetate</strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Clinical Endpoints<sup>a</sup></strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>No. subjects</p></td><td style="vertical-align:top"><p>408</p></td><td style="vertical-align:top"><p>410</p></td><td style="vertical-align:top"><p>363</p></td><td style="vertical-align:top"><p>359</p></td><td colspan="2" style="vertical-align:top"><p>350</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Annualised relapse rate</p></td><td style="vertical-align:top"><p>0.364</p></td><td style="vertical-align:top"><p>0.172***</p></td><td style="vertical-align:top"><p>0.401</p></td><td style="vertical-align:top"><p>0.224***</p></td><td colspan="2" style="vertical-align:top"><p>0.286*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rate ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.47</p><p>(0.37, 0.61)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.56</p><p>(0.42, 0.74)</p></td><td colspan="2" style="vertical-align:top"><p>0.71</p><p>(0.55, 0.93)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Proportion relapsed</p></td><td style="vertical-align:top"><p>0.461</p></td><td style="vertical-align:top"><p>0.270***</p></td><td style="vertical-align:top"><p>0.410</p></td><td style="vertical-align:top"><p>0.291**</p></td><td colspan="2" style="vertical-align:top"><p>0.321**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.51</p><p>(0.40, 0.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.66</p><p>(0.51, 0.86)</p></td><td colspan="2" style="vertical-align:top"><p>0.71</p><p>(0.55, 0.92)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Proportion with 12-week confirmed disability</p><p>progression</p></td><td style="vertical-align:top"><p>0.271</p></td><td style="vertical-align:top"><p>0.164**</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128<sup>#</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.156<sup>#</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>(0.44, 0.87)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.79</p><p>(0.52, 1.19)</p></td><td colspan="2" style="vertical-align:top"><p>0.93</p><p>(0.63, 1.37)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Proportion with 24 week confirmed disability</p><p>progression</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128#</p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.078#</p></td><td colspan="2" style="vertical-align:top"><p>0.108#</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.77</p><p>(0.52, 1.14)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>(0.37, 1.03)</p></td><td colspan="2" style="vertical-align:top"><p>0.87</p><p>(0.55, 1.38)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>MRI Endpoints</strong> <sup>b</sup>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>No. subjects</p></td><td style="vertical-align:top"><p>165</p></td><td style="vertical-align:top"><p>152</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>147</p></td><td colspan="2" style="vertical-align:top"><p>161</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mean (median) number of new or newly enlarging T2</p><p>lesions over 2 years</p></td><td style="vertical-align:top"><p>16.5</p><p>(7.0)</p></td><td style="vertical-align:top"><p>3.2</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>19.9</p><p>(11.0)</p></td><td style="vertical-align:top"><p>5.7</p><p>(2.0)***</p></td><td colspan="2" style="vertical-align:top"><p>9.6</p><p>(3.0)***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lesion mean ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.15</p><p>(0.10, 0.23)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.29</p><p>(0.21, 0.41)</p></td><td colspan="2" style="vertical-align:top"><p>0.46</p><p>(0.33, 0.63)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mean (median) number of</p><p>Gd lesions at 2 years&nbsp;</p></td><td style="vertical-align:top"><p>1.8</p><p>(0)</p></td><td style="vertical-align:top"><p>0.1</p><p>(0)***</p></td><td style="vertical-align:top"><p>2.0</p><p>(0.0)</p></td><td style="vertical-align:top"><p>0.5</p><p>(0.0)***</p></td><td colspan="2" style="vertical-align:top"><p>0.7</p><p>(0.0)**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.10</p><p>(0.05, 0.22)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.26</p><p>(0.15, 0.46)</p></td><td colspan="2" style="vertical-align:top"><p>0.39</p><p>(0.24, 0.65)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Mean (median) number of new T1 hypointense lesions</p></td><td style="vertical-align:top"><p>5.7</p><p>(2.0)</p></td><td style="vertical-align:top"><p>2.0</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>8.1</p><p>(4.0)</p></td><td style="vertical-align:top"><p>3.8</p><p>(1.0)***</p></td><td colspan="2" style="vertical-align:top"><p>4.5</p><p>(2.0)**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>over 2 years</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lesion mean ratio&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.28</p><p>(0.20, 0.39)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.43</p><p>(0.30, 0.61)</p></td><td colspan="2" style="vertical-align:top"><p>0.59</p><p>(0.42, 0.82)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p><sup>a</sup>All analyses of clinical endpoints were intent-to-treat; <sup>b</sup>MRI analysis used MRI cohort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*P-value &lt; 0.05; **P-value &lt; 0.01; ***P-value &lt; 0.0001; #not statistically significant Efficacy in patients with high disease activity:&nbsp;</p><p>Consistent treatment effect on relapses in a subgroup of patients with high disease activity was observed, whilst the effect on time to 3-month sustained disability progression was not clearly established. Due to the design of the studies, high disease activity was defined as follows: - Patients with 2 or more relapses in one year, and with one or more Gd-enhancing lesions on brain MRI (n=42 in DEFINE; n=51 in CONFIRM) or,&nbsp;</p><p>- Patients who have failed to respond to a full and adequate course (at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years (n=177 in DEFINE; n=141 in CONFIRM).</p><p>Paediatric population&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Dimethyl fumarate Capsules in one or more subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orally administered Dimethyl fumarate Capsules (dimethyl fumarate) undergoes rapid presystemic hydrolysis by esterases and is converted to its primary metabolite, monomethyl fumarate, which is also active. Dimethyl fumarate is not quantifiable in plasma following oral administration of Dimethyl fumarate Capsules. Therefore, all pharmacokinetic analyses related to dimethyl fumarate were performed with plasma monomethyl fumarate concentrations. Pharmacokinetic data were obtained in subjects with multiple sclerosis and healthy volunteers.</p><p><u>Absorption&nbsp;</u></p><p>The T<sub>max</sub> of monomethyl fumarate is 2 to 2.5 hours. As Dimethyl fumarate Capsules gastroresistant hard capsules contain microtablets, which are protected by an enteric coating, absorption does not commence until they leave the stomach (generally less than 1 hour). Following 240 mg twice a day administered with food, the median peak (C<sub>max</sub>) was 1.72 mg/l and overall (AUC) exposure was 8.02 h.mg/l in subjects with multiple sclerosis. Overall, C<sub>max</sub> and AUC increased approximately dose- proportionally in the dose range studied (120 mg to 360 mg). In subjects with multiple sclerosis, two 240 mg doses were administered 4 hours apart as part of a three times a day dosing regimen. This resulted in a minimal accumulation of exposure yielding an increase in the median Cmax of 12% compared to the twice daily dosing (1.72 mg/l for twice daily compared to 1.93 mg/l for three times daily) with no safety implications. Food does not have a clinically significant effect on exposure of dimethyl fumarate. However, Dimethyl fumarate Capsules should be taken with food due to improved tolerability with respect to flushing or gastrointestinal adverse events (see section 4.2).</p><p><u>Distribution&nbsp;</u></p><p>The apparent volume of distribution following oral administration of 240 mg Dimethyl fumarate Capsules varies between 60 L and 90 L. Human plasma protein binding of monomethyl fumarate generally ranges between 27% and 40%.</p><p><u>Biotransformation&nbsp;</u></p><p>In humans, dimethyl fumarate is extensively metabolised with less than 0.1% of the dose excreted as unchanged dimethyl fumarate in urine. It is initially metabolised by esterases, which are ubiquitous in the gastrointestinal tract, blood and tissues, before it reaches the systemic circulation. Further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. A single 240 mg <sup>14</sup>C-dimethyl fumarate dose study identified glucose as the predominant metabolite in human plasma. Other circulating metabolites included fumaric acid, citric acid and monomethyl fumarate. The downstream metabolism of fumaric acid occurs through the tricarboxylic acid cycle, with exhalation of CO<sub>2</sub> serving as a primary route of elimination.</p><p><u>Elimination&nbsp;</u></p><p>Exhalation of CO<sub>2</sub> is the primary route of dimethyl fumarate elimination accounting for 60% of the dose. Renal and faecal elimination are secondary routes of elimination, accounting for 15.5% and 0.9% of the dose respectively.</p><p>The terminal half-life of monomethyl fumarate is short (approximately 1 hour) and no circulating monomethyl fumarate is present at 24 hours in the majority of individuals. Accumulation of parent drug or monomethyl fumarate does not occur with multiple doses of dimethyl fumarate at the therapeutic regimen. <u>Linearity</u>&nbsp;</p><p>Dimethyl fumarate exposure increases in an approximately dose proportional manner with single and multiple doses in the 120 mg to 360 mg dose range studied.</p><p><strong>Pharmacokinetics in special patient groups&nbsp;</strong></p><p>Based on the results of Analysis of Variance (ANOVA), body weight is the main covariate of exposure (by C<sub>max</sub> and AUC) in relapsing remitting multiple sclerosis (RRMS) subjects, but did not affect safety and efficacy measures evaluated in the clinical studies.&nbsp;</p><p>Gender and age did not have a clinically significant impact on the pharmacokinetics of dimethyl fumarate. The pharmacokinetics in patients aged 65 and over has not been studied.</p><p><u>Paediatric population&nbsp;</u></p><p>The pharmacokinetics in patients below the age of 18 has not been studied.</p><p><u>Renal impairment&nbsp;</u></p><p>Since the renal pathway is a secondary route of elimination for dimethyl fumarate accounting for less than 16% of the dose administered, evaluation of pharmacokinetics in individuals with renal impairment was not conducted.</p><p><u>Hepatic impairment&nbsp;</u></p><p>As dimethyl fumarate and monomethyl fumarate are metabolised by esterases, without the involvement of the CYP450 system, evaluation of phamacokinetics in individuals with hepatic impairment was not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions described in the Toxicology and Reproduction toxicity sections below were not observed in clinical studies, but were seen in animals at exposure levels similar to clinical exposure levels.</p><p>Mutagenesis&nbsp;</p><p>Dimethyl fumarate and mono-methylfumarate were negative in a battery of in vitro assays (Ames, chromosomal aberration in mammalian cells). Dimethyl fumarate was negative in the in vivo micronucleus assay in the rat.</p><p>Carcinogenesis&nbsp;</p><p>Carcinogenicity studies of dimethyl fumarate were conducted for up to 2 years in mice and rats. Dimethyl fumarate was administered orally at doses of 25, 75, 200 and 400 mg/kg/day in mice, and at doses of 25, 50, 100, and 150 mg/kg/day in rats. In mice, the incidence of renal tubular carcinoma was increased at 75 mg/kg/day, at equivalent exposure (AUC) to the recommended human dose. In rats, the incidence of renal tubular carcinoma was increased at 100 mg/kg/day, approximately 2 times higher exposure than the recommended human dose. The relevance of these findings to human risk is unknown.</p><p>The incidence of squamous cell papilloma and carcinoma in the nonglandular stomach (forestomach) was increased at equivalent exposure to the recommended human dose in mice and below exposure to the recommended human dose in rats (based on AUC). The forestomach in rodents does not have a human counterpart.&nbsp;</p><p>Toxicology&nbsp;</p><p>Nonclinical studies in rodent, rabbits, and monkeys were conducted with a dimethyl fumarate suspension (dimethyl fumarate in 0.8% hydroxypropyl methylcellulose) administered by oral gavage. The chronic dog study was conducted with oral administration of the dimethyl fumarate capsule.&nbsp;</p><p>Kidney changes were observed after repeated oral administration of dimethyl fumarate in mice, rats, dogs, and monkeys. Renal tubule epithelial regeneration, suggestive of injury, was observed in all species. Renal tubular hyperplasia was observed in rats with life time dosing (2-year study). In dogs that received daily oral doses of dimethyl fumarate for 11 months, the margin calculated for cortical atrophy was observed at 3 times the recommended dose based on AUC. In monkeys that received daily oral doses of dimethyl fumarate for 12 months, single cell necrosis was observed at 2 times the recommended dose based on AUC. Interstitial fibrosis and cortical atrophy were observed at 6 times the recommended dose based on AUC. The relevance of these findings to humans is not known.&nbsp;</p><p>In the testes, degeneration of the seminiferous epithelium was seen in rats and dogs. The findings were observed at approximately the recommended dose in rats and 3 times the recommended dose in dogs (AUC basis). The relevance of these findings to humans is not known.</p><p>Findings in the forestomach of mice and rats consisted of squamous epithelial hyperplasia and hyperkeratosis; inflammation; and squamous cell papilloma and carcinoma in studies of 3 months or longer in duration. The forestomach of mice and rats does not have a human counterpart.</p><p>Reproduction toxicity&nbsp;</p><p>Oral administration of dimethyl fumarate to male rats at 75, 250, and 375 mg/kg/day prior to and during mating had no effects on male fertility up to the highest dose tested (at least 2 times the recommended dose on an AUC basis). Oral administration of dimethyl fumarate to female rats at 25, 100, and 250 mg/kg/day prior to and during mating, and continuing to Day 7 of gestation, induced reduction in the number of estrous stages per 14 days and increased the number of animals with prolonged diestrus at the highest dose tested (11 times the recommended dose on an AUC basis). However, these changes did not affect fertility or the number of viable fetuses produced.</p><p>Dimethyl fumarate has been shown to cross the placental membrane into fetal blood in rats and rabbits, with ratios of fetal to maternal plasma concentrations of 0.48 to 0.64 and 0.1 respectively. No malformations were observed at any dose of dimethyl fumarate in rats or rabbits. Administration of dimethyl fumarate at oral doses of 25, 100, and 250 mg/kg/day to pregnant rats during the period of organogenesis resulted in maternal adverse effects at 4 times the recommended dose on an AUC basis, and low fetal weight and delayed ossification (metatarsals and hindlimb phalanges) at 11 times the recommended dose on an AUC basis. The lower fetal weight and delayed ossification were considered secondary to maternal toxicity (reduced body weight and food consumption).&nbsp;</p><p>Oral administration of dimethyl fumarate at 25, 75, and 150 mg/kg/day to pregnant rabbits during organogenesis had no effect on embryo-fetal development and resulted in reduced maternal body weight at 7 times the recommended dose and increased abortion at 16 times the recommended dose, on an AUC basis.</p><p>Oral administration of dimethyl fumarate at 25, 100, and 250 mg/kg/day to rats during pregnancy and lactation resulted in lower body weights in the F1 offspring, and delays in sexual maturation in F1 males at 11 times the recommended dose on an AUC basis. There were no effects on fertility in the F1 offspring. The lower offspring body weight was considered secondary to maternal toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dimethyl Fumarate Delayed Release Capsules 240mg</p><p>Silicified microcrystalline cellulose, croscormellose sodium, Talc, colloidal silicon dioxide, magnesium stearate, methacrylic acid and Methyl Methacrylate co-polymer, Titanium Dioxide, polysorbate 80, Isopropyl Alcohol, triethyl citrate, methacrylic acid co-polymer type C, Poloxamer 407, calcium silicate, sodium bicarbonate, sodium lauryl sulphate.</p><p>The capsule shell is composed of Gelatin and Titanium Dioxide.</p><p>The imprinting ink contains the following inactive ingredients: black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.<br />&quot; Keep the blisters in the outer carton in order to protect from light&quot;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&rsquo;s Alu- Triplex (PVC/PE/Pvdc) blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Ltd. 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Limited Unit-III, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>